Samsung NeuroLogica and MedyMatch in Strategic Alliance
29 March, 2017
"MedyMatch artificial intelligence applications will leap this paradigm forward: enabling CT to provide clinical answers and not just images.”
MedyMatch Technology from Tel-aviv Israel, and Samsung NeuroLogica Corporation, the Danvers, Massachussetts healthcare subsidiary of Samsung Electronics, announced a collaboration to integrate artificial intelligence (AI) clinical decision support applications with Samsung NeuroLogica’s medical imaging hardware. This collaboration will create support tools which will help caregivers to quickly and accurately assess patients in prehospital environments.
The first step will be to integrate of MedyMatch’s AI technologies into the mobile stroke unit (MSU) – ambulance or other emergency vehicle – that is equipped with a Samsung NeuroLogica CereTom CT (computed tomography) scanner. This will allow the team onboard to quickly assess whether a patient is having a stroke caused by a blood clot or hemorrhage. The very first step in the assessment is to rule out brain bleed, and this is where MedyMatch’s technology will be utilized. Since “Time Lost is Brain Lost,” rapid patient assessment is essential in choosing the most appropriate treatment, even while in transit to the hospital.
Smart Imaging is smarter
“We are on the threshold of the next evolutionary step in Imaging”, said Gene Saragnese, Chairman & CEO of MedyMatch, “Imaging technological development has been historically focused on providing clinicians the best possible image. MedyMatch artificial intelligence applications will leap this paradigm forward, enabling Imagers such as CT to provide clinical answers and not just images.”
A stroke occurs when blood flow to the brain is interrupted by a blockage or a rupture in an artery, depriving brain tissue of oxygen. Stroke is the fourth leading cause of death in the United States and a leading cause of disability. Close to 800,000 Americans suffer a stroke each year. Most suffer ischemic stroke, which occurs when blood flow to the brain is obstructed by a clot in a blood vessel. Fortunately, ischemic stroke can be treated effectively with a tissue plasminogen activator (tPA), a drug that if administered within three hours of the first signs of stroke dissolves a clot to improve blood flow back to the affected part of the brain.
Smarter is faster
Unfortunately, it can take an hour after a stroke patient arrives in the emergency department to receive treatment because of the time needed to determine which kind of stroke the patient is having. “Technology that can assist the physicians in recognizing brain bleeds more quickly, will lead to faster decision making for the patient and better outcomes,” said Dr. Peter Rasmussen, Medical Director of Cleveland Clinic’s Distance Health Program. “Emergency treatment is needed to recognize and treat brain bleeds as quickly as possible.”
“This is just one example of how Intelligent imaging can have a positive impact,” said Robert Mehler, COO of MedyMatch. “We envision that medical imaging devices will be A.I. enabled with decision support to assist the physician in patient care and optimize the clinical workflow.”
Phillip Sullivan, President and CEO of Samsung NeuroLogica: “We are seeing worldwide demand and implementation of our Mobile Stroke Units, with new installations in New York, Trenton, Chicago, Bangkok, Alberta, India and Germany. Our collaboration with MedyMatch brings advanced technology to support better treatment of stroke.”
The portable X-ray and CT scan device market growth is expected to grow approximately 7.6% CAGR to 2020, reaching $8.41B, and MedyMatch is at the forefront of enabling this industry growth.